tetanus vaccine, adsorbed / Sinovac - LARVOL DELTA

Safety and Immunogenicity of Single-Dose of Adsorbed Tetanus Vaccine in Adults Aged 18-44 Years: Randomized, Double-Blind, Positive-Controlled Phase I/III Clinical Trial. (PubMed, Vaccines (Basel)) - "All the reported ARs were mild or moderate, and no SAEs were associated with the vaccination. The new adsorbed tetanus vaccine demonstrated favorable safety and comparable immunogenicity to the marketed control vaccine, with a significantly higher antibody GMC, supporting its clinical application in tetanus prevention."

Clinical • Journal • Infectious Disease • Tetanus

Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population (clinicaltrials.gov) - P3 | N=1260 | Completed | Sponsor: Sinovac Life Sciences Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Mar 2024 | Trial primary completion date: Sep 2024 ➔ Oct 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Tetanus